Two more Vioxx victories for Merck

Share this article:
Merck was awarded one federal and one state court victory related to Vioxx last week. Alabama state court jurors ruled in Merck’s favor Friday, rejecting the claims of a plaintiff who blamed the drugmaker’s withdrawn painkiller Vioxx for his heart attack in 2001. On Wednesday, a federal court in New Orleans also ruled in favor of Merck. “Juries continue to determine that Merck acted responsibly in its research of Vioxx and provided the appropriate information about Vioxx to patients and the medical community,” Merck EVP and general counsel Kenneth Frazier said in a statement. Attorneys for the plaintiff in the Alabama case argued that 57-year-old Gary Albright should receive as much as $5.75 million in his lawsuit filed last year. But jurors speaking with attorneys and reporters in the courtroom after the verdict said Albright had too many health problems before his heart attack to blame Vioxx. In a separate case, a federal jury in New Orleans last Wednesday ruled the drug maker adequately warned of the risks associated with the medicine. The lawsuit was filed by plaintiff Anthony Wayne Dedrick, 50, of Waynesboro, TN, who argued that his heart attack resulted from Merck failing to warn doctors adequately about the risk posed by taking the withdrawn painkiller Vioxx. Merck has won four federal cases involving Vioxx and lost one. In state courts, the drugmaker has won four cases and lost three. A case in New Jersey has been ordered to retrial after jurors sided with Merck.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...